$110 Million in Aggregate Financings to Accelerate Genio’s U.S. Commercial Launch

$110 Million in Aggregate Financings to Accelerate Genio’s U.S. Commercial Launch

Mont-Saint-Guibert, Belgium – June 10, 2026, 10:30 pm CET / 04:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), has completed a $95 million equity financing and anticipates receipt of the $15 million second tranche of its European Investment Bank loan, which represents an aggregate of $110 million in new capital. This milestone marks a turning point for Nyxoah as the Company enters its next phase of U.S.-driven growth and long-term value creation.

Financing and Leadership Transition Highlights

  • $110 million in new capital
    • $95 million in equity financing with strong insider participation
    • $15 million anticipated second tranche of its European Investment Bank loan by the end of June 2026
  • Planned acceleration of U.S. commercialization of Genio. Continued adoption of Genio in the U.S. where the Company now has 40 sales reps in place under an experienced U.S.-based commercial leadership team

“This is a defining moment for Nyxoah,” said Olivier Taelman, Chief Executive Officer. “Building on the strong momentum of our first two commercial quarters in the U.S., this capital will allow Nyxoah to accelerate the commercial ramp of Genio in the United States and deliver on its mission for OSA patients.”

Robert Taub, Chairman of the Nyxoah Board, added: “The strong participation of both new and existing investors is a powerful endorsement of our Genio technology, our strategy and our team. With its financial foundation now secured, Nyxoah is well positioned to create long term value for shareholders.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the completed offering and the intended use of proceeds therefrom; the Company’s capital position; the drawdown under the European Investment Bank loan; its planned CEO transition; the Genio system; the potential advantages of the Genio system; and the Company’s commercialization strategy and growth in the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah

John Landry, CFO

[email protected]

Rémi Renard, Head of Investor Relations & Corporate Communication

[email protected]

Attachment


GlobeNewswire Distribution ID 1001187075

Nyxoah Announces Closing of Underwritten Public Offering

REGULATED INFORMATION

Nyxoah Announces Closing of Underwritten Public Offering

Mont-Saint-Guibert, Belgium – June 10, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public offering in the United States, which included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 55,232,558 ordinary shares at an offering price of $1.72 (EUR 1.48) per share, before underwriting discounts and commissions. The total gross proceeds from the public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nyxoah, is approximately $95.0 million (approximately EUR 81.9 million).

Nyxoah intends to use the net proceeds from the offering (i) for expanding commercialization activities in the United States; (ii) to further finance research and development activities related to Genio system upgrades, re-designing its products for manufacturability and cost reduction initiatives, and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; (iii) to advance commercialization of the Genio system in its initial target markets outside of the United States and to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; and (iv) for other general corporate purposes, including, but not limited to, working capital, repayment of debt financing, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations. In the second quarter of 2026, Nyxoah intends to draw EUR 13.8 million from the second tranche of the Company’s European Investment Bank loan.

BofA Securities acted as the lead bookrunner for the offering. Bank Degroof Petercam SA/NV acted as an additional bookrunner and B. Riley acted as a co-manager for the offering.

The public offering in the United States was made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-285982) that was filed by Nyxoah with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on April 1, 2025. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by contacting BofA Securities at 201 North Tryon Street, NC1-022-02-25, Charlotte, NC 28255-0001, Attention: Prospectus Department, at [email protected] or by telephone at 1-800-294-1322.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (as amended, the “EU Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. The offering referred to in this announcement was not subject to a prospectus approved by the Belgian Financial Services and Markets Authority (the “FSMA”). The Company has filed with the FSMA an information document in relation to the admission to listing and trading on the regulated market of Euronext in Brussels of 55,232,558 ordinary shares in accordance with Article 1(5)(ba) (iii) and Annex IX of the EU Prospectus Regulation. The information document was drawn up in English and made available through the following link: https://investors.nyxoah.com/financials. In any member state of the European Economic Area (the “Member States”), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and received approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements may be identified by words such as “expects,” “potential,” “could,” or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company’s commercialization strategy and entrance to the U.S. market; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies; and statements relating to the offering, the anticipated proceeds from the offering and the use thereof. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 26, 2026, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Attachment

GlobeNewswire Distribution ID 1001187069

Bitget CFD Rolls Out Zero-Fee Mode Amid Daily Volume Growth Toward $10B

Bitget CFD Rolls Out Zero-Fee Mode Amid Daily Volume Growth Toward $10B

Bitget CFD Rolls Out Zero-Fee Mode Amid Daily Volume Growth Toward $10B

Bitget CFD Rolls Out Zero-Fee Mode Amid Daily Volume Growth Toward $10B

 

VICTORIA, Seychelles, June 10, 2026 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today announced the launch of Zero-Fee Mode for Bitget CFD, introducing a commission-free account option designed to make CFD trading more flexible, transparent, and accessible.

The launch comes as Bitget CFD continues to scale rapidly, with daily trading volume reaching $8 billion in May and moving closer to the $10 billion milestone. This growth reflects rising demand for multi-asset trading access, as users increasingly seek efficient ways to trade global markets within a unified platform.

Bitget CFD now offers a dual-account structure that gives users greater control over how they trade. The existing ECN Mode remains available for professional, short-term, and high-frequency traders who prefer tighter spreads with volume-based commissions, while the new Zero-Fee Mode is designed for users who favor a more straightforward cost structure with standard spreads and no trading commissions.

The update is driven by growing user demand and feedback around more intuitive trading experiences. Rather than imposing a single model, Bitget CFD now gives users the flexibility to choose the account type that best matches their capital size, trading strategy, experience level, and personal preferences.

“Multi-asset access is becoming the new standard for trading platforms, and CFD is central to how Bitget is delivering that future,” said Gracy Chen, CEO of Bitget“By introducing Zero-Fee Mode, we are providing users with greater flexibility to engage in global markets, further advancing our mission to make financial opportunities more accessible within a single, integrated ecosystem.”

This introduction follows a string of successes for Bitget CFD, including its debut industry honor as the Best Global Multi-Asset Trading Platform at the Online Trading Expo. Previously, the platform noted that non-crypto assets accounted for up to 40% of trading activity on certain days this year. Gold and U.S. indices, such as the NAS100, remain the platform’s two most popular trading products, driving overall volume growth.

Within Bitget’s UEX vision, Bitget CFD plays a key role in connecting crypto and traditional market access through one integrated trading ecosystem. The addition of Zero-Fee Mode strengthens Bitget’s broader effort to make multi-asset trading more accessible, flexible, and aligned with different user needs.

For more information about the launch, visit here.

About Bitget

Bitget is the world’s largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 100+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships with LALIGA and MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry’s lowest fees and highest liquidity across 150 regions worldwide.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord

For media inquiries, please contact: [email protected]

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bcc77153-f7cf-40a5-8e4a-10979c9f2206

GlobeNewswire Distribution ID 1001186973

Bitget Continues Stock Spot Expansion With 30 New Listings Across Leading Market Themes

Bitget Continues Stock Spot Expansion With 30 New Listings Across Leading Market Themes

Bitget Continues Stock Spot Expansion With 30 New Listings Across Leading Market Themes

Bitget Continues Stock Spot Expansion With 30 New Listings Across Leading Market Themes

 

VICTORIA, Seychelles, June 10, 2026 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange, has expanded its stock spot lineup with the listing of 30 new stock spot assets, further widening users’ access to traditional market opportunities under the recent launch of Stock 2.0. The newly listed assets include rNASA, rBMNR, rDIS, rROKU, and rLCID, and were made available on June 8, 2026.

The latest additions cover a diverse range of companies and investment themes, spanning space innovation, entertainment, consumer brands, enterprise technology, healthcare, defense, cloud infrastructure, education technology, and electric vehicles. The newly supported assets include Tema Space Innovators ETF, BitMine Immersion Technologies, AbbVie, Automatic Data Processing, BlackSky Technology, BWX Technologies, CAVA Group, Celsius Holdings, Cognex, CRISPR Therapeutics, The Walt Disney Company, DigitalOcean, Duolingo, Guidewire Software, Himax Technologies, Hewlett Packard Enterprise, The Coca-Cola Company, Lucid Group, and Lockheed Martin, among others.

Following the recent integration of 49 U.S. equities and ETFs, as well as the expansion of the Bitget Unified Trading Account to include tokenized stocks as margin assets, this latest update provides users with even broader exposure to established global corporations and emerging growth companies across high-activity market sectors. Bitget enhances the accessibility of traditional financial products alongside its robust crypto and market instrument suites, enabling a more comprehensive investment experience through a single, unified platform.

The addition further strengthens Bitget’s Universal Exchange strategy, which brings together crypto assets, stocks, ETFs, commodities, foreign exchange products, precious metals, derivatives, and tokenized financial instruments within a unified trading environment. The platform currently offers access to more than 100 tokenized stocks and ETFs, alongside a growing suite of traditional financial products designed to help users navigate opportunities across global markets.

The announcement follows Bitget’s continued expansion across stock perpetuals, CFDs, IPO Prime products, tokenized equities, and Reality, its regulated real-world asset issuance platform. Together, these developments reflect Bitget’s broader vision of creating a more connected trading experience across both digital assets and traditional financial markets.

For more information, visit here.

About Bitget

Bitget is the world’s largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 100+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships with LALIGA and MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry’s lowest fees and highest liquidity across 150 regions worldwide.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord

For media inquiries, please contact: [email protected]

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/69425e08-5fb1-432d-8466-a807af1eb166

GlobeNewswire Distribution ID 1001186917

Pioneering evidence shows how entrepreneurship model can reduce extreme poverty among refugees

Mary selling goods at the market

Mary selling goods at the market in the Bidi Bidi refugee settlement in Uganda with her business associates

 

  • New studies show DREAMS program boosts incomes, savings, and resilience in refugee communities across East Africa 
  • The IKEA Foundation has committed $7.4m to fund the next stage of DREAMS in Ethiopia while the Conrad N. Hilton Foundation has granted $3.5m in funding for the next stage of DREAMS in Uganda

NAIROBI, Kenya, June 10, 2026 (GLOBE NEWSWIRE) — New evidence released today shows that a combined approach of entrepreneurship support and market access can significantly reduce extreme poverty among refugees and host communities in East Africa.

Two randomized controlled trials (RCTs) of the DREAMS (Delivering Resilient Enterprises and Market Systems) program—implemented by Village Enterprise and Mercy Corps—found that participating households saw meaningful economic gains within a year, even in some of the world’s most challenging refugee settings.

The studies, conducted by independent evaluator IDinsight, found that compared to a control group, DREAMS participants increased:

  • Monthly household consumption by 17% in Uganda and 9% in Ethiopia
  • Savings by over 90% in both countries, strengthening financial buffers and resilience to economic and climate shocks
  • Household assets by 20–24%, as participants acquired livestock, built homes, and invested in tools.

The program reached more than 22,000 households across some of the largest refugee settlements in the world—Rhino Camp and Bidi Bidi in Uganda’s West Nile region and three refugee settlements in Dollo Ado, Ethiopia.

DREAMS combines Village Enterprise’s 12-month poverty graduation program—which equips ultra-poor households with the skills, financial capital, and mentoring needed to start businesses—with market systems development (MSD), delivered by the global humanitarian and development organization Mercy Corps. MSD promotes connections with local private sector actors in key industries to strengthen local markets.

At a time of unprecedented cuts to humanitarian aid, the findings point to a highly cost-effective, scalable model that supports refugees and host communities to move beyond aid dependence, create sustainable livelihoods, and provide for their families and children.

Mary selling goods at the market in the Bidi Bidi refugee settlement in Uganda with her business associates

Jjumba Martin for Village Enterprise

People participating in DREAMS reported meaningful changes in their lives such as being able to buy more nutrient-rich foods such as beef, fish, and milk, as well as pay for the costs of sending their children to school, including paying for fees, books, and transportation. Viola first arrived in the Bidi Bidi refugee settlement from South Sudan and now owns a hair salon. “I had to carry my one-year-old daughter, and our hunger and fatigue made the journey even harder. We arrived in Uganda with nothing,” she said. “I didn’t know that I could change like this. I think of the day I fled my home and how far I’ve come, and I’m amazed.”

Nurina, a refugee from Somalia who now lives in Ethiopia, said: “Because of my disability, I used to prefer to stay in one place. I felt isolated. My neighbors used to underestimate me, and I wasn’t perceived as important. But now they see that I can earn a living, save money, and provide for my children. They come to me for advice. They ask me to explain what I’ve learned from Village Enterprise. This program was a turning point for my entire family.”

The boost to household assets—20% higher than control groups in Uganda and 24% higher in Ethiopia—included livestock, agricultural tools, and investments in housing and solar panels, as well as furniture such as mattresses, beds, and tables.

A development blueprint

The RCTs have measured the impact of the program in Uganda and Ethiopia, but demonstrate the potential of this solution for the 8.7 million people living in refugee settlements globally.

Recognizing the success of DREAMS, the program will continue to be supported:

  • In Ethiopia—by the IKEA Foundation, which has committed $7.4 million to fund the next stage of DREAMS and further embed the program into local government systems. A key focus of the grant will be to evaluate why the program works in different contexts, and optimizing the approach to be able to scale in these complex settings.
  • In Uganda—by the Conrad N. Hilton Foundation’s commitment of $3.5 million for DREAMS’ next stage through March 2029, as well as an evaluation of how DREAMS can embed into existing early childhood development programs across Uganda, Kenya, Tanzania, and Mozambique.

As climate change and conflict drive increased mass displacement, DREAMS showcases how host countries can support refugees to generate income, create sustainable livelihoods, and contribute to local economies. In both Ethiopia and Uganda, the RCTs found DREAMS is projected to yield twice the value of its costs through increased household consumption and asset accumulation if effects are sustained for five years.

Sazini Mojapelo, CEO of Village Enterprise, said: “At a time when humanitarian budgets are shrinking, we need solutions that deliver real, lasting results for the millions of refugees worldwide. DREAMS shows that with the right support, refugees and host communities living in extreme poverty can build businesses, grow their incomes, and provide for their families—ultimately, reducing their reliance on aid. We’re grateful to the IKEA Foundation and the Hilton Foundation for their continued support of this work and helping bring DREAMS to more communities and refugees in Ethiopia and Uganda.”

Tjada McKenna, CEO of Mercy Corps, said: “Lasting change doesn’t come from aid alone; it comes from access to opportunity. This evidence shows that when refugees are connected to functioning markets, supply chains, and customers, they build, earn, and contribute. If we want a future where everyone can prosper, we need to invest in the systems that make that possible.”

Alison Connor, Chief Impact Officer at IDinsight, said: “Rigorous evidence on what works for refugees remains scarce, and this evaluation adds meaningfully to that gap. We tested what happens when poverty graduation and market systems development are combined in refugee settings. Across Uganda and Ethiopia, participating households saw meaningful gains in consumption, income, savings, and assets within months of program completion, at returns that compare favorably to other livelihood programs in the region. As the humanitarian sector faces difficult funding decisions, findings like these can help direct resources toward approaches with a credible evidence base.”

Rediet Abiy Kassaye, Programme Manager at the IKEA Foundation, said: “These results show what is possible when refugees and host communities are given the opportunity to rebuild their lives with dignity, stability, and hope. We are proud to support the next phase of DREAMS in Ethiopia and to continue working alongside Village Enterprise and Mercy Corps to help families recover from displacement and create new opportunities for themselves and their communities. Together, we see the potential for small businesses and vibrant local markets to create lasting opportunities for families and communities for generations to come.”

Barri Shorey, Senior Program Officer, Refugees, Disasters and Aviation at the Conrad N. Hilton Foundation, said: “DREAMS demonstrates the power of investing in long-term economic solutions for refugees and host communities. We’re proud to support the next phase of this work in Uganda because the model helps families build sustainable livelihoods, strengthen household stability, and create healthier futures for their children—a true two generation approach! Integrating DREAMS with early childhood development efforts across East Africa creates an opportunity to support caregivers and young children together, helping families build more secure and productive futures.”

Notes to Editors 

  • About the DREAMS program
    • As part of Village Enterprise’s poverty graduation model, participating households were organized into business savings groups of 30 households, designed to encourage them to pool savings, support each other, and issue small loans.
    • Mercy Corps connected the businesses with private sector actors in key industries including poultry, sunflower, soybean, sesame, and sheep and goat fattening.
    • Households were encouraged to set up multiple businesses across the key industries, allowing them to be more resilient against setbacks caused by common threats such as crop failure, extreme weather, poultry mortality due to disease, and theft.
    • While the control groups in both Uganda and Ethiopia did not receive any funding, and remained reliant on previous income avenues, some experienced indirect benefits from the program. Some control households informally accessed funding by borrowing money or getting goods on credits through friends and neighbors enrolled in the program.
  • About the RCT in Uganda
    • Village Enterprise equipped 12,000 households with business training, $204 in seed capital (in two installments), and ongoing mentorship to start and sustain businesses.
    • The seed capital was shared between business groups of three households, which in turn were included in the business savings groups.
    • 6,560 households participated in the RCT, which was conducted between 2022 and 2025, and the 12-month DREAMS program was rolled out to staggered cohorts throughout this time.
    • To ensure the program did not contribute to local inflation, cohorts were staggered to begin four months after the start of the cohort before. You can read the RCT results in full here.
    • These results are based on the findings from the first endline survey, conducted between April and July 2025, capturing outcomes short to medium term results approximately six to 18 months after the participants had finished the program.
    • A second survey is planned to take place one year later, in 2026, to measure the longer-term impacts of the program.
  • About the RCT in Ethiopia
    • Village Enterprise equipped 10,800 participants in Dollo Ado with business training, $500 in seed capital, and mentoring to start and sustain businesses.
    • The seed capital was shared between business groups of three households, which in turn were included in business savings groups.
    • The RCT in Ethiopia was conducted by IDinsight between 2023 and 2026 and evaluated the impact of the poverty graduation model in communities where Mercy Corps was strengthening market systems development, as well as the full DREAMS program, on household economic productivity and welfare, perceived well-being, and women’s empowerment among refugee and host households.
    • 6,151 households participated in the RCT, of which 2,050 received the full DREAMS program.
    • These results are based on the findings from the first endline survey, with data collected between October and December 2025, capturing outcomes approximately six to 18 months after implementation.
    • You can read the RCT results in full here.

About Village Enterprise
Village Enterprise’s mission is to end extreme poverty in rural Africa through entrepreneurship, innovation, and collective action. We work with vulnerable women, refugees, and youth who are most impacted by climate change, conflict, and displacement, and equip them with skills and resources to launch climate-smart businesses, build savings, and put themselves and their families onto a sustainable path out of extreme poverty. Village Enterprise has started over 119,000 businesses and positively transformed the lives of over 2.3 million people in Ethiopia, Kenya, Rwanda, Uganda, Congo-Brazzaville, the Democratic Republic of the Congo, Madagascar, Mozambique, Nigeria, and Tanzania.

About Mercy Corps
Mercy Corps is a global team of nearly 4,300 humanitarians working to create a world where everyone can prosper. 95% of our team members are from the countries where they work. In 46 countries affected by conflict, disaster, poverty, and climate change, we work alongside communities, local governments, forward-thinking corporations, and social entrepreneurs to meet urgent needs and develop long-term solutions to make lasting change possible. In 2025, Mercy Corps reached over 36.5 million people. Learn more at www.mercycorps.org.

About IDinsight
IDinsight is a global nonprofit that equips leaders with the data, evidence, and technology to improve lives at scale. We partner with governments, NGOs, and funders to support decisions at every stage of the impact journey – from bold pilots to nationwide scale-ups. Our teams bring rigorous evidence, cutting-edge methods, and practical insights, so leaders can design and deliver programs that truly change lives.

Media contact:
[email protected]
+44 7388 003595

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6044f789-0bf6-4524-9715-9f9f68a92f53

GlobeNewswire Distribution ID 1001186813

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation

PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further defining the potential of mogamulizumab in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, two subtypes of cutaneous T-cell lymphoma, will be featured at the World Congress of Cutaneous Lymphomas (WCCL) in Montréal, Canada.

Drawing on complementary evidence streams, including patient-reported outcomes, comparative-effectiveness estimates, molecular biomarker signals, and real-world utilization, these analyses collectively provide a more complete understanding of the therapeutic profile and potential of mogamulizumab.

“The research being presented at WCCL reflects our continued commitment to generating evidence beyond initial clinical trials for mogamulizumab in patients with relapsed or refractory mycosis fungoides and Sézary syndrome,” said Daniela van Eickels, MD, PhD, MPH, Chief Medical Officer, Kyowa Kirin North America. “In these difficult-to-treat blood cancers, innovative clinical research and real-world data generation is essential to advancing and informing treatment strategies. We look forward to sharing our findings and exchanging ideas with the expert community.”

WCCL Presentations:

Improved symptoms and health-related quality of life in patients with mycosis fungoides and Sézary syndrome treated with mogamulizumab in the PROSPER study
Oral Presentation; Scientific Session 8A
Friday, June 26, 3:30-4:30 PM ET

Outcomes in relapsed/refractory mycosis fungoides or Sézary syndrome from the MAVORIC trial mogamulizumab arm versus a real-world Australian cohort receiving vorinostat
(Collaborative Study)
Oral Presentation; Scientific Session 3B
Thursday, June 25, 2:30-3:30 PM ET

Overall survival in patients with mycosis fungoides or Sézary syndrome in Denmark: comparative effectiveness of mogamulizumab versus standard of care
Oral Presentation; Scientific Session 3B
Thursday, June 25, 2:30-3:30 PM ET

Targeted sequencing in patients with relapsed/refractory mycosis fungoides mogamulizumab or Sézary syndrome treated with mogamulizumab in the MOGA-2MG-Q4W clinical trial 
Oral Presentation; Scientific Session 4B
Thursday, June 25, 3:40-5:20 PM ET

Mogamulizumab treatment for mycosis fungoides in clinical practice in France: data from the ongoing multicentric prospective observational PROMED study
Exhibit Hall Poster Session
Thursday-Saturday, June 25-27

U.S. POTELIGEO (mogamulizumab-kpkc) Indication
POTELIGEO injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

WARNINGS AND PRECAUTIONS

Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).

Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.

Infections: Monitor patients for signs and symptoms of infection and treat promptly.

Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.

Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

ADVERSE REACTIONS

The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information in full Prescribing Information as well as Patient Information.

About Kyowa Kirin
Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.

CONTACT: 
Susan Thiele
Head of Therapeutic Communications, North America
[email protected]

GlobeNewswire Distribution ID 9734113